A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

Clinical trial NCT06525350 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06525350
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression

Start date: 2024-07-01
Primary completion: 2026-12-25
Enrollment: 256

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.